Tao Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Tao Capital Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,683	Closed	-$82.9K	–	9
2025 Q3	$82.9K	Hold	5,683	–	–	0.06%	10
2025 Q2	$63.9K	Hold	5,683	–	–	0.05%	9
2025 Q1	$32.4K	Hold	5,683	–	–	0.03%	9
2024 Q4	$55.8K	Hold	5,683	–	–	0.04%	10
2024 Q3	$46.3K	Sell	5,683 -1	-0%	-$10	0.04%	10
2024 Q2	$76K	Hold	5,684	–	–	0.06%	10
2024 Q1	$264K	Hold	5,684	–	–	0.25%	9
2023 Q4	$385K	Hold	5,684	–	–	0.35%	8
2023 Q3	$412K	Hold	5,684	–	–	0.32%	11
2023 Q2	$423K	Hold	5,684	–	–	0.31%	12
2023 Q1	$303K	Hold	5,684	–	–	0.24%	14
2022 Q4	$385K	Buy	+5,684	New	+$523K	0.29%	15

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tao Capital Management's DNA Position: Q4 2025 in Review

Tao Capital Management sold out of Ginkgo Bioworks (DNA) in Q4 2025, closing a stake of 5,683 shares — an estimated $82.9K sold.

Tao Capital Management first reported a position in DNA in Q4 2022 and held it in 12 quarters. The position peaked at $423K in Q2 2023. 181 funds tracked by Wall St. Rank hold DNA as of Q4 2025.

Tao Capital Management reported no remaining Ginkgo Bioworks position as of Q4 2025 after selling out during the quarter.
Tao Capital Management sold 5,683 Ginkgo Bioworks shares in Q4 2025, an estimated $82.9K.
Tao Capital Management first reported a position in Ginkgo Bioworks in Q4 2022 and held it in 12 quarters.
Tao Capital Management's Ginkgo Bioworks position peaked at $423K in Q2 2023.
181 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2025.

Based on Tao Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.